文献速递前列腺癌

18F-Fluciclovine PET对前列腺癌生化复发治疗决策的影响:LOCATE试验结果

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
PubMed 文献 · J Urol · 2019-01-01

LOCATE是一项前瞻性多中心试验,纳入213例根治性治疗后生化复发且常规影像阴性或不确定的前列腺癌患者,行18F-Fluciclovine PET/CT后57%检出复发灶,59%患者管理方案改变(78%为重大改变)。未来需研究管理改变是否改善结局。

要点

  • 18F-Fluciclovine PET/CT在57%生化复发患者中检出复发灶。
  • 59%患者扫描后管理改变,其中78%为重大改变。
  • 最常见重大改变为挽救/非治愈系统治疗转为观察等待(25%)。

核心结论

  • 18F-Fluciclovine PET/CT在多数生化复发前列腺癌患者中检出至少一处复发灶,并频繁导致管理方案重大改变。
  • 未来需研究管理改变是否带来结局改善。

研究设计与样本

  • 前瞻性多中心LOCATE试验,纳入213例可评估患者,中位年龄67岁,中位PSA 1.00 ng/ml。
  • 患者为根治性治疗后生化复发且常规影像阴性或不确定,行18F-Fluciclovine PET/CT。
  • 治疗医师在扫描前后填写问卷记录治疗计划变化。

主要发现

  • 122/213例(57%)检出18F-Fluciclovine亲和病灶。
  • 126/213例(59%)扫描后管理改变,其中98/126例(78%)为重大改变。
  • 88/126例(70%)的管理改变由PET/CT阳性发现推动。
  • 最常见重大改变:挽救或非治愈系统治疗转为观察等待32/126例(25%)。
  • 非治愈系统治疗转为挽救治疗30/126例(24%),挽救治疗转为非治愈系统治疗11/126例(9%)。

临床怎么用

  • 对根治性治疗后生化复发且常规影像阴性或不确定的前列腺癌患者,可考虑行18F-Fluciclovine PET/CT以指导治疗决策。

局限性

  • 尚未确定管理改变是否改善结局,需未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prospective, multicenter LOCATE (F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent. MATERIALS AND METHODS: Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. F-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) as major and changes in a modality (eg modified radiotherapy fields) as other. RESULTS: Between June 2016 and May 2017, 213 evaluable patients with a median age of 67 years and median prostate specific antigen 1.00 ng/ml were enrolled in study. F-fluciclovine avid lesions were detected in 122 of the 213 patients (57%). Overall 126 of the 213 patients (59%) had a change in management after the scan, which were major in 98 of 126 (78%) and in 88 (70%) were informed by positive positron emission tomography/computerized tomography findings. The most frequent major changes were from salvage or noncurative systemic therapy to watchful waiting (32 of 126 cases or 25%), from noncurative systemic therapy to salvage therapy (30 of 126 or 24%) and from salvage therapy to noncurative systemic therapy (11 of 126 or 9%). CONCLUSIONS: F-fluciclovine positron emission tomography/computerized tomography detected 1 or more recurrence sites in the majority of men with biochemical recurrence, frequently resulting in major changes to management plans. Future studies will be planned to determine whether a management change leads to improved outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2019. PMID: 30179618. doi:10.1016/j.juro.2018.08.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。